Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients

BACKGROUND: Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation. Cytomegalovirus genotyping was performed to identi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Douglas, Cameron M, Barnard, Richard, Holder, Daniel, Leavitt, Randi, Levitan, Diane, Maguire, Maureen, Nickle, David, Teal, Valerie, Wan, Hong, van Alewijk, Dirk C J G, van Doorn, Leen-Jan, Chou, Sunwen, Strizki, Julie
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7075417/
https://ncbi.nlm.nih.gov/pubmed/31781762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiz577
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars